Convergent Therapeutics
Biotechnology, 601 Lexington Ave, Cambridge, Massachusetts, 10022, United States, 1-10 Employees
Who is CONVERGENT THERAPEUTICS
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeu...
Read More
-
Headquarters: 601 Lexington Ave, Cambridge, Massachusetts, 10022, United States
-
Date Founded: 2021
-
Employees: 1-10
-
Revenue: $50 Million to $100 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from CONVERGENT THERAPEUTICS
Convergent Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Convergent Therapeutics
Answer: Convergent Therapeutics's headquarters are located at 601 Lexington Ave, Cambridge, Massachusetts, 10022, United States
Answer: Convergent Therapeutics's official website is https://convergentrx.com
Answer: Convergent Therapeutics's revenue is $50 Million to $100 Million
Answer: Convergent Therapeutics's SIC: 2834
Answer: Convergent Therapeutics's NAICS: 325412
Answer: Convergent Therapeutics has 1-10 employees
Answer: Convergent Therapeutics is in Biotechnology
Answer: Convergent Therapeutics contact info: Phone number: Website: https://convergentrx.com
Answer: Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month